PDCD1 and neoplasm: We postulate that the therapeutic benefit observed in our study is a consequence of vorinostat-induced increase in tumor cells immunogenicity through HLA-DR up-regulation, associated with increase in T cells recognition, function and activation by anti-PD1 and anti-CTLA-4 blockades.